FRACTIONATED REIRRADIATION OF RECURRENT IDH WILDTYPE GLIOBLASTOMA: HIGHER REIRRADIAITON DOSE AND SAFETY

被引：0
|
作者：
Lecompte, Michael [1 ]
Vuppala, Neil [2 ]
Reyes, Juan [3 ]
Page, Brandi [1 ]
Croog, Victoria [1 ]
Huang, Ellen [1 ]
Redmond, Kristin [1 ]
Kleinberg, Lawrence [1 ]
机构：
[1] Johns Hopkins Sch Med, Baltimore, MD USA
[2] Alabama Coll Osteopath Med, Dothan, AL USA
[3] Johns Hopkins Univ, Baltimore, MD USA
来源：
NEURO-ONCOLOGY | 2024年 / 26卷
关键词：
D O I：
10.1093/neuonc/noae165.0301
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
RADT-17
引用
收藏
页数：2
相关论文
共 44 条
  • [41] Phase 1, Dose Escalation, Nonrandomized, Open-Label, Clinical Trial Evaluating the Safety and Preliminary Efficacy of Allogenic Adipose-Derived Mesenchymal Stem Cells for Recurrent Glioblastoma: A Clinical Trial Protocol
    Ramos-Fresnedo, Andres
    Al-Kharboosh, Rawan
    Twohy, Erin L.
    Basil, Aleeshba N.
    Szymkiewicz, Ewa C.
    Zubair, Abba C.
    Trifiletti, Daniel M.
    Durand, Nisha
    Dickson, Dennis W.
    Middlebrooks, Erik H.
    Abarbanel, David N.
    Tzeng, Stephany Y.
    Almeida, Joao Paulo
    Chaichana, Kaisorn L.
    Green, Jordan J.
    Sherman, Wendy J.
    Quinones-Hinojosa, Alfredo
    NEUROSURGERY PRACTICE, 2023, 4 (04):
  • [42] A phase I/IIa, open-label, multicenter, non-randomized clinical trial to assess the safety and efficacy of CYNK-001 in combination with recombinant human interleukin 2 in adults with recurrent resection eligible IDH1 wild-type glioblastoma (GBM)
    Bota, Daniela Annenelie
    Badie, Behnam
    Heimberger, Amy B.
    Majd, Nazanin
    Awadalla, Mark S.
    Colerangle, John
    He, Shawn
    Koppisetti, Sharmila
    van der Touw, William
    Hariri, Robert
    Pecora, Andrew L.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [43] A 2-PART SAFETY AND EXPLORATORY EFFICACY RANDOMISED DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF A 1:1 RATIO OF CANNABIDIOL AND DELTA-9-TETRAHYDROCANNABINOL (CBD:THC) PLUS DOSE-INTENSE TEMOZOLOMIDE IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME (GBM)
    Short, Susan C.
    Little, Christian
    NEURO-ONCOLOGY, 2017, 19 : 13 - 13
  • [44] A two-part safety and exploratory efficacy randomized double-blind, placebo-controlled study of a 1:1 ratio of the cannabinoids cannabidiol and delta-9-tetrahydrocannabinol (CBD:THC) plus dose-intense temozolomide in patients with recurrent glioblastoma multiforme (GBM).
    Twelves, Chris
    Short, Susan
    Wright, Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345